Biobeat Technologies has raised $50 million in a series B round to help boost the commercialization of its blood pressure ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...

Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Koroshetz’s exit—expected Jan. 24—means that 14 of the NIH’s 27 units will be helmed by interim leaders. NINDS acting deputy ...

Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. | Cardiovascular (CV) disease is ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Elon Musk’s Neuralink is shifting into high gear for 2026 as the company’s co-founder touts changes to the brain-computer ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...